CRF Health Announces an Open ePRO Integration Interface
CRF Health
announced an open ePRO integration interface, which enables Sponsors and CROs to integrate their own eClinical systems with CRF Health’s ePRO platform, TrialMax, to provide data collected from patients in real time to all study stakeholders.
The TrialMax Synapse open interface integrates ePRO data collected with CRF Health’s TrialMax platform to other eClinical systems in real time using the CDISC ODM standard. The current studies integrated to a EDC system are seeing a variety of benefits, including the enabling of sites to view all study data in one system, increasing the efficiency of drug accountability, facilitating data management, and allowing easier correlation of adverse events.
Rachael King, CEO of CRF Health, comments, “We have seen a significant increase in interest for integrating ePRO data to other eClinical systems, and are currently using integration in several studies. As the use of integration has exceeded all of our expectations, we decided to offer the possibility to all Sponsors and CROs that we are working with.”
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Reblozyl Misses Primary Endpoint in Phase III Myelofibrosis Trial but Shows Clinical Promise
July 21st 2025The Phase III INDEPENDENCE trial (NCT04717414) failed to meet its primary endpoint of achieving transfusion independence in patients with myelofibrosis-associated anemia treated with Reblozyl (luspatercept-aamt).
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
